3D tumour spheroid model studies on glioblastoma ©Lizenz: CC-BY 4.0
©Lizenz: CC-BY 4.0
3-dimensional model studies, as shown here on a glioblastoma spheroid, facilitate the measurement of the in vivo, biologically relevant effect of antitumour therapeutics.
Design: L. Gerlitz, D. Zweytick, data from Maxian et al, Biomedicines (2021), licence: CC-BY 4.0

Innovative model studies

- to investigate the efficacy, specificity and mechanisms of action of new cancer therapeutics

Models used:

  • Liposome-based cancer and non-cancer mimics for the optimisation of lipid-targeting peptides

  • In vitro 2D cancer and non-cancer cell cultures to identify cancer-specific peptides, including studies on patient-derived cells (collaboration with Beate Rinner, Pathology, MUG)

  • In vitro 3D cancer and non-cancer cell cultures to better mimic in vivo conditions and investigate peptide penetration and effects on tumour spheroids with and without tumour stroma

  • Blood-brain barrier models for the development of peptide drugs for neurological tumours

  • Immune system models to investigate the immunomodulatory effects of peptides

  • Organoid models, in cooperation with Beate Rinner (Pathology, MUG) and Florian Kai Gröber-Becker (Fraunhofer Institute for Silicate Research, Würzburg, Germany)

  • In vivo human and mouse models at the Medical University of Graz (Beate Rinner, Pathology, MUG)

 


Publications:

Riedl et al, 2014, 2015, 2017,doi: 10.1007/s10534-014-9749-0doi: 10.1016/j.bbamem.2015.07.018doi.org/10.18632/oncotarget.17823 Wodlej et al, 2019, doi: 10.1371/journal.pone.0211187 Grissenberger et al, 2020, doi.org/10.1016/j.bbamem.2020.183264 Maxian et al, 2021, doi: 10.3390/ijms22168469 Wussmann et al, 2022, doi: 10.3390/biomedicines10112961.